Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping

Cancer Discovery

Volumn 5, Issue 8, 2015, Pages 842-850

  Paik, Paul K ^a,b   Drilon, Alexander ^a,b   Fan, Pang Dian ^a   Yu, Helena ^a,b   Rekhtman, Natasha ^a   Ginsberg, Michelle S ^a   Borsu, Laetitia ^a   Schultz, Nikolaus ^a   Berger, Michael F ^a,b   Rudin, Charles M ^a,b   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CRIZOTINIB; FLUORODEOXYGLUCOSE; SCATTER FACTOR RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; RNA SPLICING;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DOSE REDUCTION; EXON SKIPPING; FATIGUE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; TREATMENT RESPONSE; VERY ELDERLY; ADENOCARCINOMA; ALTERNATIVE RNA SPLICING; ANTAGONISTS AND INHIBITORS; CANCER GRADING; CANCER STAGING; COPY NUMBER VARIATION; EXON; GENETICS; LUNG NEOPLASMS; METABOLISM; METASTASIS; MORTALITY; MUTATION; RNA SPLICING; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DNA COPY NUMBER VARIATIONS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RNA SPLICE SITES; TREATMENT OUTCOME;

EID: 84938815085     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-1467     Document Type: Article

References (25)

1. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014;64:252-71.
2. Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA 2014;311:1998-2006.
3. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013;31:1089-96.
4. Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013;39:793-801
5. Krishnaswamy S, Kanteti R, Duke-Cohan JS, Loganathan S, Liu W, Ma PC, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009;15:5714-23
6. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489: 519–25.
7. The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511: 543-50.
8. Spigel D, Edelman M, O’Byrne K, Paz-Ares L, Shames D, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol 32:5s, 2014 (suppl; abstr 8000).
9. Camidge D, Ou S-H, Shapiro G, Otterson G, Villacruz L, Villalona-Calero M, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). J Clin Oncol 32:5s, 2014 (suppl; abstr 8001)
10. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c MET mutational analysis in small cell lung cancer: novel juxtamem-brane domain mutations regulating cytoskeletal functions. Cancer Res 2003;63:6272–81.
11. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88.
12. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006;66:283-9.
13. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009;4:5-11.
14. Seo J-S, Ju YS, Lee W-C, Shin J-Y, Lee JK, BleazardT, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19.
15. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, et al. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adeno carcinomas. Clin Cancer Res2 012;18:4910–8.
16. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, et al. EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther 2013;12:220-9.
17. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061–8.
18. Gao J, Aksoy B A, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6:pl1-pl.
19. Ilagan JO, Ramakrishnan A, Hayes B, Murphy ME, Zebari AS, Bradley P, et al. U2AF1 mutations alter splice site recognition in hematological malignancies. Genome Res 2014;25:14-26.
20. Yakes FM, Chen J, Tan J, Yamaguchi K, Shi Y, Yu P, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308.
21. Katayama R, Kobayashi Y, Friboulet L, Lockerman EL, Koike S, Shaw AT, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res 2015;21:166-74.
22. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiprolif erative and antiangiogenic mechanisms. Cancer Res 2007;67: 4408-17.
23. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, BlumenscheinG R, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small- cell lung cancer. J Clin Oncol 2013;31:4105-14.
24. Cheng D, Mitchell T, Zehir A, Shah R, Benayed R, Syed A, et al. MSK-IMPACT: a hybridization capture-based next generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn 2015;17:251-64.
25. Geiss G K, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotech 2008;26:317-25